Estrogen agonistic/antagonistic effects of miproxifene phosphate (TAT- 59)

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 2, 2000, Pages 133-141

  Shibata, Jiro ^a   Toko, Toshiyuki ^a   Saito, Hitoshi ^a   Fujioka, Akio ^a   Sato, Kouji ^a   Hashimoto, Akihiro ^a   Wierzba, Konstanty ^a   Yamada, Yuji ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Antitumor activity; Estrogen antiestrogen; Miproxifene phosphate (TAT 59); Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; ESTROGEN; ETHINYLESTRADIOL; MIPROXIFENE PHOSPHATE; RALOXIFENE; TAMOXIFEN; TOREMIFENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METABOLISM; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; ESTROGEN ACTIVITY; FEMALE; HUMAN; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR XENOGRAFT; UTERUS;

EID: 0033983181     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050021     Document Type: Article

References (25)

1. 1. Baum M (1998) Tamoxifen and breast. Ear J Cancer 34 [Suppl 4]: S7
2. 2. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU (1994) Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93: 63
3. 3. Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G (1988) Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 45: 344
4. 4. Daniel P, Gaskell SJ, Bishop H, Campbell C, Nicholson RI (1981) Determination of tamoxifen and biologically active metabolites in human breast tumours and plasma. Eur J Cancer 17: 1183
5. 5. Dehal SS, Kupfer D (1997) CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 57: 3402
6. 6. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 1
7. 7. Frolik CA, Bryant HU, Black EC, Magee DE, Chandrasekhar S (1996) Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. Bone 18: 621
8. 8. Furr BJA, Jordan VC (1984) The pharmacology and clinical use of tamoxifen. Pharmacol Ther 25: 127
9. 9. Legha SS, Davis HL, Muggia FM (1978) Hormonal therapy of breast cancer: new approaches and concepts. Ann Intern Med 88: 69
10. 10. Lippman M, Bolan G, Huff K (1976) The effects of estrogens and antiestrogens of hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36: 4595
11. 11. Morimoto K, Abe O, Kinoshita H (1998) Steady state and disappearance of the metabolites of miproxifene phosphate in the treatment of breast cancer. Jpn J Cancer Chemother 25: 1565
12. 12. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning D, Nicholson RI (1995) Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87: 746
13. 13. Palkowitz AD, Glasebrook AL, Thrasher KJ, Hauser KL, Short LL, Phillips DL, Muehl BS, Sato M, Shetler PK, Cullinan GJ, Pell TR, Bryant HU (1997) Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]benzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator. J Med Chem 40: 1407
14. 14. Powles TJ, Hardly JR, Ashley SE, Farrington GM, Cosgrove D, Davey JB, Dowsett M, McKinna JA, Nash AG, Sinnett HD, Tillyer CR, Treleaven JG (1989) A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 60: 126
15. 15. Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF, Sporn MB (1985) Type β transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci USA 82: 119
16. 16. Rochefort H, Borgna JL, Evans E (1983) Cellular and molecular mechanism of action of antiestrogens. J Steroid Biochem 19: 69
17. 17. Ross W, Huber P, Oeze L, Eppenberger U (1982) Hormone dependency and the action of tamoxifen in human mammary carcinoma cells. Anticancer Res 2: 157
18. 18. Sato M, Rippy MK, Bryant HU (1996) Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 10: 905
19. 19. Taylor CM, Blanchard B, Zava DT (1984) Estrogen receptor-mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen. Cancer Res 44: 1409
20. 20. Toko T, Sugimoto Y, Matsuo K, Yamasaki R, Takeda S, Wierzba K, Asao T, Yamada Y (1990) TAT-59, a new triphenylethylene derivative with anti-tumor activity against hormone dependent tumors. Eur J Cancer 26: 397
21. 21. Toko T, Matsuo K, Shibata J, Wierzba K, Nukatsuka M, Takeda S, Yamada Y, Asao A, Hirose T, Sato B (1992) Interaction of DP-TAT-59, an active metabolite of new triphenylethylene derivative (TAT-59), with estrogen receptors. J Steroid Biochem Mol Biol 43: 507
22. 22. Toko T, Shibata J, Sugimoto Y, Yamaya H, Yoshida M, Ogawa K, Matsushima E (1995) Comparative pharmacodynamic analysis of TAT-59 and tamoxifen in rats bearing DMBA-induced mammary carcinoma. Cancer Chemother Pharmacol 37: 7
23. 23. Toko T, Shibata J, Nukatsuka M, Yamada Y (1997) Antiestrogenic action of DP-TAT-59, an active metabolite of TAT-59 against human breast cancer. Cancer Chemother Pharmacol 39: 390
24. 24. Van-Leeuwen FE, Bergman L, Benraadt J (1998) Dose risk of endometrial cancer increases with longer duration of tamoxifen use? Eur J Cancer 34: S44
25. 25. Wieder R, Shimkin MB (1964) An improved method of producing hormone-cholesterol pellets. J Natl Cancer Inst 32: 957